Compare FRHC & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FRHC | CYTK |
|---|---|---|
| Founded | N/A | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.7B | 7.6B |
| IPO Year | 1996 | 2004 |
| Metric | FRHC | CYTK |
|---|---|---|
| Price | $127.26 | $60.38 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 18 |
| Target Price | N/A | ★ $86.00 |
| AVG Volume (30 Days) | 105.6K | ★ 1.6M |
| Earning Date | 01-01-0001 | 05-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.38 | N/A |
| Revenue | ★ $2,050,527,000.00 | $13,368,000.00 |
| Revenue This Year | N/A | $37.53 |
| Revenue Next Year | N/A | $214.81 |
| P/E Ratio | $52.56 | ★ N/A |
| Revenue Growth | ★ 25.41 | N/A |
| 52 Week Low | $107.98 | $29.31 |
| 52 Week High | $194.01 | $70.98 |
| Indicator | FRHC | CYTK |
|---|---|---|
| Relative Strength Index (RSI) | 60.06 | 38.75 |
| Support Level | $118.69 | $59.23 |
| Resistance Level | $129.28 | $65.93 |
| Average True Range (ATR) | 5.22 | 2.59 |
| MACD | 1.48 | -0.74 |
| Stochastic Oscillator | 93.55 | 9.49 |
Freedom Holding Corp is a holding company with its subsidiary it is engaged in securities brokerage, securities dealing for customers and account, market-making activities, investment research, investment counseling, investment banking services, retail and commercial banking, insurance products, payment services, and information processing services. It acts as a professional participant through its subsidiaries on the Kazakhstan Stock Exchange (KASE), Moscow Exchange (MOEX), Saint-Petersburg Exchange (SPB), the Ukrainian Exchange, the Uzbek Republican Currency Exchange (UZCE), and the Republican Stock Exchange of Tashkent (UZSE). Its segments are Brokerage, Banking, Insurance, and Others.
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.